NCT01419977View on ClinicalTrials.gov

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2014

Conditions
Sickle Cell DiseaseVaso-occlusive Crisis
Interventions
DRUG

Placebo

Normal saline solution, administered by nursing staff once daily

DRUG

Dalteparin

Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin

Trial Locations (1)

27710

Duke University, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

Eisai Limited

INDUSTRY

lead

Duke University

OTHER